{"id":"W2059228450","doi":"10.1016/j.ejca.2014.04.008","title":"A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Erlotinib; Rash; Medicine; Gemcitabine; Internal medicine; Pancreatic cancer; KRAS; Erlotinib Hydrochloride; Epidermal growth factor receptor; Oncology; Phases of clinical research; Progressive disease; Gastroenterology; Adverse effect; Cancer; Toxicity; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001540495,0.001499451,0.002720293,0.0005262892,0.0005263634,0.001390085,0.000772698,0.001465323,0.003869317],"category_scores_gemma":[0.0007902074,0.000604398,0.001657338,0.0005248322,0.001076711,0.001420139,0.0004074871,0.003572766,0.001010895],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009762759,"about_ca_system_score_gemma":0.001262846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001154606,"about_ca_topic_score_gemma":0.002944922,"domain_scores_codex":[0.9996159,0.0001777718,0.0000206761,0.00006343094,0.00002285996,0.00009921394],"domain_scores_gemma":[0.9994496,0.0001056588,0.00008338886,0.00006043789,0.00002978643,0.0002711892],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7921541,0.05734648,0.004627084,0.00138697,0.001795158,0.0004336986,0.0003740203,0.004457737,0.03348987,0.0003393818,0.003897749,0.0996978],"study_design_scores_gemma":[0.6269819,0.3542289,0.008686142,0.00006145617,0.0007474677,0.0004323901,0.000151319,0.001388378,0.003689039,0.0002267734,0.00335774,0.0000484402],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933402,0.002217134,0.0003536569,0.0005275797,0.0001337515,0.001268997,0.0006888527,0.00007322049,0.001396501],"genre_scores_gemma":[0.9881504,0.003448965,0.001140941,0.0007305864,0.0001394353,0.001397908,0.001904703,0.00004580108,0.003041297],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003869317,"threshold_uncertainty_score":0.01294416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03875342993914899,"score_gpt":0.396565932724892,"score_spread":0.3578125027857431,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}